23 completed, 2 active not recruiting, 2 terminated, 1 withdrawn. 11 Phase 3, 9 Phase 2, 4 Phase 4, 2 Not applicable, 2 Phase 1.
Follow icatibant: new trials by email Literature Review of icatibant trials Research Report on icatibant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema Icatibant Injection (Icanticure®) - Bradykinin-mediated Angioedema, Hereditary Angioedema (HAE) | Phase 4 | Completed | Nang Kuang Pharmaceutical Co., Ltd. | 5 | 2024-09-27 | 2025-12-18 |
| Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor Icatibant, Placebo - Intradialytic Hypotension | Phase 3 | Active not recruiting | Vanderbilt University Medical Center | 26 | 2023-12-11 | 2026-10-22 |
| A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema Icatibant - Hereditary Angioedema (HAE) | Completed | Takeda | 32 | 2022-08-24 | 2026-08-07 | |
| Inhibition of Bradykinin in COVID-19 Infection With Icatibant Icatibant, 0.9% Sodium Chloride Injection - SARS CoV 2 Infection | Phase 2 / Phase 3 | Completed | Belfast Health and Social Care Trust | 32 | 2022-05-16 | 2023-09-07 |
| Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection Firazyr, SoC - COVID-19 Pneumonia | Phase 2 | Completed | Sebastian Videla | 73 | 2021-04-12 | 2022-08-03 |
| Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study). C1 Inhibitor Human, Icatibant Injection, Placebo - Covid19 | Phase 2 | Completed | GCS Ramsay Santé pour l'Enseignement et la Recherche | 44 | 2021-02-04 | 2022-12-22 |
| A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema TAK-667 - Hereditary Angioedema | Phase 3 | Completed | Takeda | 2 | 2021-01-15 | 2022-03-29 |
| I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Remdesivir, Imatinib Mesylate, Dexamethasone - COVID-19 | Phase 2 | Active not recruiting | QuantumLeap Healthcare Collaborative | 1500 | 2020-07-31 | 2026-03-16 |
| Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 LCZ 696, Icatibant, placebo - Heart Failure | Phase 4 | Completed | Vanderbilt University Medical Center | 46 | 2019-11-01 | 2026-08-11 |
| FIRAZYR General Drug Use-Results Survey (Japan) Firazyr - Hereditary Angioedema (HAE) | Completed | Shire | 179 | 2018-11-20 | 2025-02-21 | |
| Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2 Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid - Heart Failure NYHA Class I, Heart Failure NYHA Class II | Phase 2 | Withdrawn | Vanderbilt University Medical Center | 2017-09-01 | 2018-01-11 | |
| Mitochondria and Chronic Kidney Disease Icatibant, Placebo - Hemodialysis-Induced Symptom, Mitochondrial Diseases | Phase 2 | Completed | Vanderbilt University Medical Center | 11 | 2017-08-01 | 2019-10-29 |
| A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants Icatibant - Hereditary Angioedema (HAE) | Phase 3 | Completed | Shire | 8 | 2015-03-18 | 2021-06-03 |
| Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers Icatibant (30 mg) - Hereditary Angioedema (HAE) | Phase 1 | Completed | Shire | 12 | 2014-02-21 | 2021-06-03 |
| Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema Icatibant, Placebo - Angiotensin Converting Enzyme Inhibitor Induced Angioedema | Phase 3 | Completed | Shire | 118 | 2013-12-02 | 2021-06-08 |
| A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema icatibant - Hereditary Angioedema (HAE) | Phase 3 | Completed | Shire | 32 | 2012-01-27 | 2021-06-08 |
| Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Icatibant - Hereditary Angioedema | Phase 4 | Completed | Massachusetts General Hospital | 19 | 2011-12-01 | 2016-10-18 |
| Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema icatibant, Placebo - ACE Inhibitor-associated Angioedema | Phase 4 | Terminated | Vanderbilt University Medical Center | 33 | 2011-08-01 | 2017-02-17 |
| EASSI - Evaluation of the Safety of Self-Administration With Icatibant Icatibant - Hereditary Angioedema | Phase 3 | Completed | Shire | 151 | 2009-09-25 | 2021-06-11 |
| The Effect of Ischaemic-Reperfusion and Remote Ischaemic Preconditioning in Man - A Bradykinin Dependent Pathway Forearm vascular study, Placebo, bradykinin receptor antagonist (HOE-140) - Ischaemic Heart Diseases | Not applicable | Completed | University of Edinburgh | 12 | 2009-08-01 | 2010-10-25 |
Showing 20 of 28. Sign in to see all of them.
Angioedemas, Hereditary (12) · Angioedema (5) · COVID-19 (3) · Coronary Artery Disease (2) · Cardiovascular Diseases (1) · Disease (1) · Genetic Diseases, Inborn (1) · Heart Failure (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Inflammation (1) · Joint Diseases (1) · Mitochondrial Diseases (1) · Osteoarthritis (1)
Shire (9) · Vanderbilt University Medical Center (5) · Takeda (2) · University of Edinburgh (2) · Vanderbilt University (2) · Belfast Health and Social Care Trust (1) · GCS Ramsay Santé pour l'Enseignement et la Recherche (1) · Massachusetts General Hospital (1) · Nang Kuang Pharmaceutical Co., Ltd. (1) · QuantumLeap Healthcare Collaborative (1) · Sanofi (1) · Sebastian Videla (1) · Technical University of Munich (1)
United States (15) · United Kingdom (5) · Germany (4) · Israel (4) · Japan (4) · Austria (3) · Canada (3) · Italy (3) · Spain (3) · Australia (2) · France (2) · Hungary (2) · Argentina (1) · Colombia (1) · Czechia (1)
David E Newby, PhD, FRCP (2) · Nancy J. Brown, MD (2) · Rajesh K Kharbanda, PhD, FRCP (2) · Aleena Banerji, M.D. (1) · Derek W Russell, MD (1) · Joe Kidney, MD (1) · Jorge L Gamboa, MD/PhD (1) · Kathleen D Liu, MD (1) · Laura Esserman, MD (1) · Mias Pretorius, MBChB (1) · Murat Bas, Dr. (1) · Nancy J. Brown, M.D. (1)
PMID 20818888, PMID 21873443, PMID 17073887, PMID 22123383, PMID 23167682, PMID 23361105, PMID 24111645, PMID 24438203, PMID 24749847, PMID 25198193, PMID 25629740, PMID 26556097, PMID 28552382, PMID 28601641, PMID 34473343, PMID 35413921, PMID 36610464, PMID 36883141, PMID 38035747, PMID 39592213, PMID 40462830, PMID 42028604, PMID 42630033, PMID 42799508
2004 (1), 2008 (1), 2009 (1), 2014 (1), R01HL079184 (1)